Welcome to our dedicated page for Acm Research SEC filings (Ticker: ACMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ACM Research’s wafer-cleaning and advanced-packaging systems sit at the heart of today’s most intricate chip fabs—yet the disclosures that explain how those tools drive revenue and margins stretch well past 200 pages. Finding segment sales to Chinese foundries, understanding megasonic R&D spend, or monitoring insider sales after export-control headlines can feel overwhelming. That’s why investors searching for “ACM Research SEC filings explained simply” start here.
Stock Titan applies AI-powered parsing to every document the moment it hits EDGAR. Whether you need the full ACM Research quarterly earnings report 10-Q filing, a line-by-line breakdown of the ACM Research annual report 10-K simplified, or ACM Research 8-K material events explained, our platform converts technical language into concise, decision-ready insights. Real-time alerts surface ACM Research Form 4 insider transactions, while side-by-side charts compare backlog, gross margin and regional revenue across periods—saving hours of manual cross-referencing.
Use cases are practical: track ACM Research executive stock transactions Form 4 before earnings, study wafer-cleaning tool demand swings through our ACM Research earnings report filing analysis, or verify board pay packages in the ACM Research proxy statement executive compensation section. All filing types—10-K, 10-Q, 8-K, S-8, Form 4—are covered with comprehensive, time-stamped updates. From megasonic-cleaning capacity additions to advanced-packaging revenue outlook, understanding ACM Research SEC documents with AI has never been easier.
The reporting person, Cheav Sotheara, exercised a previously issued stock option and immediately sold the acquired shares. On 08/22/2025 Mr. Cheav exercised an option with a $13.89 exercise price to purchase 11,152 shares of ACM Research Class A common stock and sold 11,152 shares that same day at $30 per share pursuant to a Rule 10b5-1 trading plan adopted May 15, 2025. After these transactions the reporting person beneficially owns 100,002 shares of Class A common stock. The Form 4 notes the underlying option covers 66,250 shares, is fully vested and exercisable, and includes a vesting schedule for remaining tranches. The reporting person is identified as Senior Vice President, Manufacturing of ACM Research (Shanghai), Inc., a subsidiary of the issuer.
Wang Jian, an officer and the Chief Executive Officer and President of ACM Research (Shanghai), Inc., reported option exercises and share sales in Form 4 filings. On 08/22/2025 he exercised 30,000 stock options with a $5.60 exercise price and immediately sold 30,000 Class A shares at $30.00, reducing his direct holdings to 253,158 shares. On 08/25/2025 he repeated the sequence—exercised 30,000 options at $5.60 and sold 30,000 shares at $32.00—leaving total direct holdings at 253,158 Class A shares. The Form notes the option was fully vested and the sales were made under a Rule 10b5-1 trading plan adopted May 20, 2025. The Form was signed by an attorney-in-fact on 08/26/2025.
ACM Research, Inc. (ACMR) Form 144 notice: An individual plans to sell 30,000 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $960,000. The filing lists 64,180,965 shares outstanding, making the proposed sale roughly 0.0467% of outstanding shares. The securities were reported as acquired by stock option exercise with a purchase date and payment date shown as 08/25/2025. The filing also discloses a sale of 30,000 shares by Jian Wang on 08/22/2025 for gross proceeds of $900,012. The notice includes the required representation that the seller does not possess undisclosed material information.
ACM Research, Inc. (ACMR) Form 144 notice: The filer intends to sell 30,000 shares of the issuer's common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $900,012.00. The shares reported were acquired and will be paid for by cash on 08/22/2025 via a stock option exercise from the issuer. The filing shows 64,180,965 shares outstanding, lists the proposed sale date as 08/22/2025 on the NASDAQ, and reports no securities sold by the person in the past three months.
Form 144 notice for ACM Research, Inc. (ACMR) shows a proposed sale of 11,152 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $334,560.00. The shares represent a portion of 64,180,965 shares outstanding and an approximate sale date of 08/22/2025. The shares were acquired on 08/22/2025 by stock option exercise from the issuer and paid in cash. The filer reports no securities sold in the past three months and affirms they are not aware of any undisclosed material adverse information.
Charles C. Pappis, a director of ACM Research, Inc. (ACMR), was granted a stock option to buy 20,000 shares of Class A common stock at an exercise price of $24.93 per share. The option was granted with an exercise date of 08/12/2025, vests immediately prior to the issuer's 2026 annual meeting subject to continued service, and expires on 08/11/2035. After this transaction, Mr. Pappis beneficially owns 20,000 underlying shares through the option, held directly.
Tracy Liu, a director of ACM Research, Inc. (ACMR), reported acquiring derivative securities on 08/12/2025. The Form 4 shows an option (exercise price $24.93) to acquire 20,000 shares of Class A common stock, recorded as an acquisition on 08/12/2025 and resulting in beneficial ownership of 20,000 shares. The option "will vest and become exercisable immediately prior to the 2026 annual meeting of stockholders," subject to continued service through the vesting date. The filing was submitted by one reporting person and signed on behalf of Ms. Liu by attorney-in-fact Mark McKechnie on 08/14/2025.
Haiping Dun, a director of ACM Research, Inc. (ACMR), reported acquiring a derivative security on 08/12/2025. The Form 4 shows an acquisition of a stock option covering 20,000 shares of Class A common stock with an exercise price of $24.93 and an expiration date of 08/11/2035. Following the reported transaction, the filing lists 20,000 shares beneficially owned directly by the reporting person.
The filing explains the option "will vest and become exercisable immediately prior to the 2026 annual meeting of stockholders," subject to continued service through the vesting date. The Form 4 was signed by an attorney-in-fact on behalf of Haiping Dun on 08/14/2025.
FAQ
What is the current stock price of Acm Research (ACMR)?
What is the market cap of Acm Research (ACMR)?
